関連する実験動画
Updated: Aug 25, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
ディピリダモールおよび他のフォスフォディエステラーゼ阻害剤は,内生性プロスタサイクリンを強化することにより,抗血栓剤として作用します
Lancet (London, England)
|June 17, 1978
まとめ
ディピリダモールの抗血栓作用は,低用量アスピリンによって強化され,高用量アスピリンによって阻害されます. この組み合わせは,この組み合わせです.
科学分野:
- 薬理学 薬理学とは
- 心血管研究 循環器科の研究
- トロンボシス (Thrombosis) とは
背景:
- ディピリダモールは,プロスタサイクリン刺激による血小板循環型AMPによって強化された,フォスフォディエステラーゼ阻害による抗血栓効果を発揮する.
- 血小板機能に対するアスピリンの効果は用量に依存し,サイクロオキシゲネーゼ活性とプロスタサイクリン形成に影響を与えます.
研究 の 目的:
- アスピリンとディピリダモールとの間の抗血栓活性に対する用量依存の相互作用を調査する.
- アスピリンによるディピリダモールの作用の強化または抑制の背後にあるメカニズムを解明する.
主な方法:
- ディピリダモール単独およびアスピリンの様々な用量との併用による抗血栓効果の評価.
- 薬剤の組み合わせに対する反応として,血小板周期的なAMPレベルとプロスタサイクリン形成の評価.
主要な成果:
- 低用量アスピリンは,血小板サイクロオキシゲネーゼを選択的に抑制し,ディピリダモールの抗血栓効果を強める.
- 高用量アスピリンは,プロスタサイクリン形成を阻害し,それによってディピリダモールの抗血栓効果を廃止する.
- 低用量アスピリンとディピリダモールで観察されたセオフィリン増強.
結論:
- アスピリンとディピリダモールの併用による抗血栓効果は,アスピリン投与量に決定的に依存しています.
- 協同作用の抗血栓剤効果を達成し,対抗性を回避するために,慎重に投与量を選択することが不可欠です.
関連する概念動画
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...